We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus

By HospiMedica International staff writers
Posted on 24 Mar 2020
Print article
Image: AT-100 (Photo courtesy of Airway Therapeutics, Inc.)
Image: AT-100 (Photo courtesy of Airway Therapeutics, Inc.)
Airway Therapeutics, Inc. (Cincinnati, OH, USA), a biopharmaceutical company, has announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).

Airway is developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing the novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response. AT-100's anti-inflammatory and anti-infective properties also make it a potential treatment for other respiratory diseases such as influenza, respiratory syncytial virus (RSV) and inflammatory diseases inside and outside the lung.

AT-100 has the potential to serve as an innovative therapy for the novel coronavirus by targeting critical stages of viral infection through facilitating the binding and clearance of the virus by lung immune cells; regulating the body's immune cells to reduce the overwhelming inflammation that is the primary mechanism of illness in severe viral infections; and inhibiting infectivity and replication for several types of bacteria and viruses, including the primary coronavirus infection and also the secondary bacterial and viral infections that often complicate the care of patients with serious infections

Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants.

"Research has demonstrated that rhSP-D plays a key role in the clearance of numerous bacteria and viruses across a range of serious respiratory diseases. As COVID-19 is a novel respiratory virus, it is important to follow the data to understand if AT-100 may be an effective therapeutic with prophylactic potential to reduce infection and inflammation in patients with COVID-19," said Marc Salzberg, M.D., president and CEO of Airway. "The COVID-19 outbreak has illuminated the urgency to identify and explore new therapies for patients in need, and Airway is committed to partnering with the National Institutes of Health to explore and advance AT-100 as a potential therapeutic option."

Related Links:
Airway Therapeutics, Inc.


Print article

Channels

Business

view channel
Illustration

Surgical Robots Market to Reach USD 13.1 Billion by 2027 Due to High Acceptance in Emerging Regions

The global surgical robots market is forecasted to reach USD 13.1 billion by 2027, driven mainly by low turn-around times and increased innovation in robotics over the coming years. Surgical robots are... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.